Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
san diego blog main
8
×
san diego top stories
8
×
biotech
boston blog main
boston top stories
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
clinical trials
amgen
cancer
fda
merck
purdue pharma
biotech ipos
bristol-myers squibb
diagnostics
dyne therapeutics
europe blog main
europe top stories
hepatitis b
What
drug
8
×
bio
roundup
brings
cancer
dyne’s
fda
immunotherapy
market
new
patients
plan
pricing
therapeutics
acquisitions
advanced
advantages
agency
aimmune
allergy
anathema
approval
approved
arrival
awaited
award
awarded
bar
biggest
build
buy
ceo
cholesterol
company
company’s
daniel
data
death
debut
decades
Language
unset
8
×
Current search:
drug
×
unset
×
" san diego blog main "
×
" san diego top stories "
×
@xconomy.com
4 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
5 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
5 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
5 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)